Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men.
We previously reported that the administration of miglitol after a meal was equally effective as administration before a meal. Since glucagon-like peptide-1 (GLP-1) reportedly promotes islet cell growth and inhibits apoptosis in animal models, an increase in GLP-1 secretion might also be beneficial for islet cell function and mass in humans. Miglitol reportedly enhances GLP-1 responses and reduces glucose-dependent insulinotropic polypeptide (GIP). However, whether the effect of miglitol on these incretins is comparable when miglitol is administered before or after a meal remains uncertain. Here, we compared the effects of the pre-meal versus post-meal administration of miglitol on the plasma active GLP-1 and total GIP levels in healthy men. Miglitol was administered according to three different intake schedules in each subject (control: no drug, intake 1: drug administered just before a meal [50 mg]; intake 2: drug administered at 30 min after the start of a meal [50 mg]). The area under the curve (AUC) of the plasma GLP-1 level for the intake 1 group was significantly greater than those of the control and intake 2 groups. The AUCs of the plasma GIP level for the intake 1 and 2 groups were significantly smaller than that of the control. The administration of miglitol just before a meal, rather than after a meal, is recommended in view of the up-regulation of GLP-1.
Aoki
Kazutaka
K
Yokosuka Kyousai Hospital, Yokosuka, Japan.
Miyazaki
Takashi
T
Nagakura
Jo
J
Orime
Kazuki
K
Togashi
Yu
Y
Terauchi
Yasuo
Y
D017485:1-Deoxynojirimycin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D018592:Cross-Over Studies; D004791:Enzyme Inhibitors / Q000008:administration & dosage; D005215:Fasting; D005502:Food; D005749:Gastric Inhibitory Polypeptide / Q000097:blood*; D052216:Glucagon-Like Peptide 1 / Q000097:blood*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000097:blood; D007700:Kinetics; D008297:Male
D001786:Blood Glucose; D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; C045621:miglitol; D017485:1-Deoxynojirimycin; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1